Abstract: An anthracene derivative with a specified asymmetrical type structure. An organic electroluminescence device which comprises at least one organic thin film layer including a light emitting layer sandwiched between a pair of electrode consisting of an anode and a cathode, wherein at least one of the organic thin film layer comprises the anthracene derivative. An organic electroluminescence device which emits blue light of enhanced purity and has a long lifetime is provided.

Abstract: This organic electroluminescence element has an organic light-emitting layer between a positive electrode and a negative electrode, wherein the organic light-emitting layer contains a 1,3,6,8-tetrasubstituted pyrene compound having a specific structure as an organic light-emitting layer forming material. Provided are an organic light-emitting layer forming material that emits blue light with a high color purity, has a high luminous efficiency, and is stable for a long duration of operation, when used singly or as a guest, an organic EL element having a high luminous efficiency and a long operation lifetime, and a high-performance organic EL display that has a high luminous efficiency and a long operation lifetime.

Abstract: The subject invention provides a pharmaceutical composition comprising N-propargyl-1(R)-aminoindan mesylate; a pharmaceutically acceptable carrier; and greater than 0.7 ppm but less than 30 ppm in total of a compound having the structure: and any salts of the compound.

Abstract: A fused polycyclic compounds is represented by the general formula (I): wherein X1 to X18 each represent, independently of one another, a hydrogen atom, a halogen atom, a cyano group, a nitro group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted aralkyl group, a substituted amino group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic group.

Abstract: Provided is a compound that is an NMDA receptor antagonist having a broader safety margin, and is useful as an agent for treating or preventing Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, or pain. A novel compound or a salt thereof, which is characterized in that it has an amino group and R1 (lower alkyl, cycloalkyl, -lower alkylene-aryl, aryl which may be substituted, and the like) on carbon atoms of indane, cyclopenta[b]thiophene, cyclopenta[b]furan, cyclopenta[b]pyridine, or cyclopenta[c]pyridine ring, or 2,3-dihydrdo-1-benzofuran, 2,3-dihydrdo-1-benzothiophene, indoline ring, or the like, and has R2 and R3 (the same or different, each lower alkyl or aryl) on carbon atoms beside them, and an NMDA receptor antagonist comprising the same as an active component.

Abstract: A novel material having high hole-transporting ability and a high glass transition temperature and having long-lasting durability is obtained. A benzofluorene compound represented by formula (1) is used. (In the formula, M is a substituted or unsubstituted aryl group having 6-40 carbon atoms or a substituted or unsubstituted heteroaryl group having 5-40 carbon atoms; Ar1 to Ar4 each independently is a substituted or unsubstituted aryl group having 6-40 carbon atoms or a substituted or unsubstituted heteroaryl group having 5-40 carbon atoms, provided that at least one of Ar1 to Ar4 is a substituent represented by any of the following formulae (2) to (5); and p is an integer of 0-2.

Abstract: The present invention relates to a method of solubilizing carbon nanotubes, to carbon nanotubes produced thereby and to uses of said carbon nanotubes.

Abstract: The present invention discloses novel and improved processes for preparation of sertraline hydrochloride crystalline form II. Thus, for example, sertraline free base is dissolved in isoamyl alcohol at 25-30° C., pH of the mass is adjusted to 2.0 with conc. hydrochloric acid (36%) at 25-30° C. and then stirred for 14 hours at 25-30° C. Filtered the solid and dried at 65° C. for 4 hours to give sertraline hydrochloride crystalline form II. The present invention also provides a novel process for preparation of sertraline hydrochloride crystalline form I.

Abstract: The present invention discloses novel and improved processes for preparation of sertraline hydrochloride crystalline form II. Thus, for example, sertraline free base is dissolved in isoamyl alcohol at 25-30° C., pH of the mass is adjusted to 2.0 with conc. hydrochloric acid (36%) at 25-30° C. and then stirred for 14 hours at 25-30° C. Filtered the solid and dried at 65° C. for 4 hours to give sertraline hydrochloride crystalline form II. The present invention also provides a novel process for preparation of sertraline hydrochloride crystalline form I.

Abstract: An electrophotographic photoreceptor comprising a layered-type photosensitive layer in which a charge generating layer containing a charge generating material and a charge transporting layer containing a charge transporting material are stacked, formed on a conductive supporting member made of a conductive material, wherein the electrophotographic photoreceptor has high sensitive characteristics to a semiconductor laser beam having a wavelength ranging from 380 to 500 nm; the charge transporting layer of the layered-type photosensitive layer contains as the charge transporting material, a triarylamine dimer compound represented by the general formula (1): wherein Ar1 and Ar2 may be the same or different, and represent an unsubstituted or substituted arylene group or heterocyclic derivative bivalent group, Ar3 and Ar4 may be the same or different, and represent an unsubstituted or substituted aryl group or heterocyclic group, R1 and R2 may be the same or different, and represent an alkyl group, m and n rep

Abstract: Provided are an organic electroluminescence device and an aromatic amine derivative for realizing the device. The aromatic amine derivative improves the luminous efficiency of an organic electroluminescence device using the derivative, and its molecules hardly crystallize. The organic electroluminescence device has an organic thin film layer composed of one or a plurality of layers including at least a light emitting layer, the organic thin film layer being interposed between a cathode and an anode, and at least one layer of the organic thin film layer, especially a hole transporting layer contains the aromatic amine derivative alone or as a component of a mixture, so the organic electroluminescence device can be produced in improved yield, and has a long lifetime.

Abstract: Compounds for utilization as anti-tumor agents against cancer and certain inflammatory and arthritic conditions designed with multiple active sites to cause inhibition and cell death synthesized from the starting compound 1,4,5,8-tetrachloroanthraquinone. Included are anti-tumor compounds of the class 1,4,5,8-tetrakis-alkylaminoalkyl, 1,4,5,8-tetrakis-hydroxyalkylaminoalkyl, 1,4,5,8-tetrakis-chloroethylamino, 1,2-bischloroethylamino-1,4,5,8-tetrakis-aminoethylamino derivatives of Anthraquinone. Also includes mixtures of groupings such as 1-aminoalkylamino-4,5,8-tris-(1,2-dimethyl)aminoalkylamino anthraquinone, 1,2-dichloroethyl 1-aminoalkyl amino-4,5,8-tris-aminoethylamino anthraquinone, bis-1,4aminoalkylamino bis-5,8-alkylaminoanthraquinone, 1,4-bis-chloroalkylamino-5,8-bisaminoalkylamino anthraquinone and others.

Abstract: The present invention relates to a novel diamine derivative, a method for preparation thereof, and an organic electronic device using the same. The diamine derivative according to the present invention can serve as a hole injecting, hole transporting, electron injecting, electron transporting, or light emitting material in an organic electronic device including an organic light emitting device. Particularly, it can be used as a light emitting material as used alone, and also serve as a light emitting host, or a light emitting dopant, in particular, a blue light emitting dopant. The organic electronic device according to the present invention exhibits excellent characteristics in terms of efficiency, drive voltage, life time, and stability.

Abstract: The present invention discloses novel and improved processes for preparation of sertraline hydrochloride crystalline form II. Thus, for example, sertraline free base is dissolved in isoamyl alcohol at 25-30° C., pH of the mass is adjusted to 2.0 with conc. hydrochloric acid (36%) at 25-30° C. and then stirred for 14 hours at 25-30° C. Filtered the solid and dried at 65° C. for 4 hours to give sertraline hydrochloride crystalline form II. The present invention also provides a novel process for preparation of sertraline hydrochloride crystalline form I.

Abstract: Provided are processes for the preparation of sertraline and sertraline hydrochloride.

Abstract: To realize extremely high luminous efficiency and to provide an organic light-emitting device having a optical output with a long lifetime. Provided is an amine compound represented by the general formula (1).

Abstract: The present invention provides a novel binaphthyl compound and an organic light emitting element having a good light emitting efficiency and a high durability at a low driving voltage.

Abstract: An organic electroluminescent device, which has, between a pair of electrodes, at least one organic layer including a light-emitting layer, in which the organic layer contains a specific tetraphenylene compound, and in which the light-emitting layer contains a phosphorescent material; and a specific tetraphenylene compound that can be used in the device.

Abstract: There are provided a compound represented by the general formula (1) and an organic light-emitting device which comprises the compound and has an optical output with remarkably high efficiency and high luminance.

Abstract: A specified aromatic amine derivative having a naphthalene structure bonding to diphenylamino group with a substituent. An organic electroluminescence device which comprises at least one organic thin film layer comprising a light emitting layer sandwiched between a pair of electrode consisting of an anode and a cathode, wherein at least one of the organic thin film layer comprises the aromatic amine derivative singly or as its mixture component. Organic electroluminescence devices having a long lifetime and a high efficiency of light emission, and aromatic amine derivatives capable of realizing such organic EL devices are provided.

Abstract: A process for isolating from a reaction mixture a salt of a mono-propargylated aminoindan, a process for isolating from a reaction mixture a crystalline diastereomeric salt of a mono-propargylated aminoindan, and a process for isolating from a reaction mixture a salt of enantiomerically pure N-propargyl-1-aminoindan or a salt of enantiomerically pure 6-(N-methyl, N-ethyl-carbamoyloxy)-N?-propargyl-1-aminoindan. The corresponding products are also disclosed.

Abstract: Novel amine compounds that can be utilized as hole transport materials, hole injection materials or the like of organic electroluminescence devices, electrophotographic receptors or the like, and their production processes are provided. The novel amine compound is represented by the following general formula (1). In the formula, R1 and R2 each independently represents hydrogen atom, a linear, branched or cyclic alkyl group or alkoxy group, an aryl group, an aryloxy group or a halogen atom; Ar1 and Ar2 each independently represents a substituted or unsubstituted aryl group or heteroaryl group, and may form a nitrogen-containing heterocyclic ring together with the nitrogen atom bonded thereto; and Ar3 each independently represents a substituted or unsubstituted phenyl group, naphthyl group, biphenylyl group, terphenylyl group, anthryl group, fluorenyl group or pyridyl group (except for amino-substituted groups); and M represents a single bond, an arylene group or a heteroarylene group.

Abstract: The present invention relates to novel processes to produce sertraline hydrochloride Form II comprising the steps of forming a solution of sertraline hydrochloride in a polar organic solvent and adding this solution to a less polar organic solvent.

Abstract: Disclosed is an organic electroluminescence device in which an organic thin film which is composed of one or more layers including at least a light-emitting layer is interposed between a cathode and an anode. Since at least one layer of the organic thin film contains a novel aromatic amine derivative, which has an asymmetric structure wherein two different amine units are bonded through a linking group, by itself or as a component of a mixture, molecules of the organic electroluminescence device. This organic electroluminescence device has a long life.

Abstract: The invention provides novel arylbicyclo[3.1.0]hexylamines, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.

Abstract: One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.

Abstract: Sertraline hydrochloride polymorphic form II is conveniently prepared by adding hydrogen chloride to solution of sertraline free amine in a ketone. In preferred processes, the solution of sertraline free amine seeded with some crystals of polymorphic form II and/or the solution is heated before addition of the hydrogen chloride.

Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.

Abstract: Antioxidants for industrial, automotive, and aviation lubricants and methods of making the same are provided. A process using alkylated diphenylamines; alkylated phenyl-?-naphthyl amines; and a metal catalyst to form oxidates is provided. The metal catalyst is a combination of a cation and an organic anion, for example, a metal acetylacetone. The reaction takes place in the presence of oxygen to form an antioxidant comprising oligomers of the alkylated diphenylamine and the alkylated phenyl-?-naphthyl amine, and a metal component of the catalyst.

Abstract: Provided are processes for the preparation of sertraline and sertraline hydrochloride.

Abstract: The present invention is directed to forms II, III, V, VI, VII, VIII, IX and X of sertraline hydrochloride and novel methods for their preparation. According to the present invention, sertraline hydrochloride polymorph II may be produced by slurrying sertraline hydrochloride polymorph VI in aprotic organic solvent. Sertraline hydrochloride polymorphic form III may be produced by heating sertraline hydrochloride polymorphs V and VI. Sertraline hydrochloride forms V and VI may be produced from either sertraline hydrochloride or sertraline base by crystallization. Sertraline hydrochloride Form VII may be produced by suspending sertraline chloride polymorph V in water, followed by filtration. Sertraline hydrochloride Forms VIII and IX may be produced by suspending sertraline base in water followed by acidification and filtration. Sertraline hydrochloride Form X may be produced by suspending sertraline hydrochloride in benzyl alcohol with heating, followed by filtration.

Abstract: The subject invention provides crystalline R(+)-N-propargyl-1-aminoindan, pharmaceutical compositions and methods of manufacture thereof.

Abstract: Provided are processes for preparation of crystalline sertraline hydrochloride Form II substantially free of other polymorphic forms of sertraline hydrochloride, preferably on an industrial scale.

Abstract: The present invention relates to the improvement of organic electroluminescent devices, in particular blue-emitting devices, by using compounds of the formula (1) as dopants in the emitting layer.

Abstract: The present invention relates to a method for the preparation of tertiary carbinamine compounds from diastereoselective allylation and crotylation of N-unsubstituted imines derived from ketones.

Abstract: An object of the present invention is to provide a novel pyrene compound. Provided is a pyrene compound represented by the following general formula (I): wherein: R1 and R2 each represent a substituted or unsubstituted alkyl group; and Ar1, Ar2, Ar3, and Ar4 each represent a substituted or unsubstituted aryl group and the like.

Abstract: There is provided an aminoanthryl derivative substitution compound represented by the following general formula (1).

Abstract: Provided are processes for the preparation of sertraline and sertraline hydrochloride.

Abstract: The present invention is directed to Form II of sertraline hydrochloride and novel methods for its preparation. According to the present invention, sertraline hydrochloride Form II may be produced directly form sertraline base or sertraline mandelate. It may also be produced from sertraline hydrochloride solvate and hydrate forms, and crystallized from new solvent systems. Pharmaceutical compositions containing sertraline hydrochloride Form II and methods of treatment using such pharmaceutical compositions are also disclosed.

Abstract: Provided are hydrogenation processes of sertraline imine intermediates with catalysts in various reactors.

Abstract: Provided is a recycling process for preparing sertraline, which may be carried out on an industrial scale.

Abstract: Compounds of formula I: where R1, R2 and R3 are the same or different and signify hydrogens, halogens, alkyl, alkylaryl, alkyloxy, hydroxy, nitro, amino, alkylcarbonylamino, alkylamino or dialkylamino group; R4 signifies hydrogen, alkyl or alkylaryl group; X is CH2, O or S, and n is 1, 2 or 3, with the proviso that if X is CH2, n is not 1, and a method for their preparation. The compounds have potentially valuable pharmaceutical properties for the treatment of cardiovascular disorders such as hypertension and chronic heart failure.

Abstract: The present invention relates to a new process for preparing sertraline hydrochloride form II.

Abstract: A method for producing aromatic amino compound (V): by synthesizing intermediate compound (IV): by the reaction of compound (I): H2N—R1 with a mixture of halogenated aryl compounds (II): Ar1—X and (III): Ar2—X in the presence of a noble metal catalyst, followed by eliminating the substituent R1 from the nitrogen atom in compound (IV) under an acidic condition or an alkaline condition or by addition of a reducing agent or an oxidizing agent. (R1: a substituent having 2 to 50 carbon atoms; Ar1 and Ar2: a substituted or unsubstituted hydrocarbon group or heterocyclic group having 6 to 50 carbon atoms and the same with or different from each other; and X: a halogen group). The aromatic amino compound useful as the charge transporting material can be produced efficiently at a great yield without using highly toxic raw materials.

Abstract: Disclosed are highly efficient multiphoton absorbing compounds and methods of their use. The compounds generally include a bridge of pi-conjugated bonds connecting electron donating groups or electron accepting groups. The bridge may be substituted with a variety of substituents as well. Solubility, lipophilicity, absorption maxima and other characteristics of the compounds may be tailored by changing the electron donating groups or electron accepting groups, the substituents attached to or the length of the pi-conjugated bridge. Numerous photophysical and photochemical methods are enabled by converting these compounds to electronically excited states upon simultaneous absorption of at least two photons of radiation. The compounds have large two-photon or higher-order absorptivities such that upon absorption, one or more Lewis acidic species, Lewis basic species, radical species or ionic species are formed.

Abstract: The present invention is directed to Form II of sertraline hydrochloride and novel methods for its preparation. According to the present invention, sertraline hydrochloride Form II may be produced directly form sertraline base or sertraline mandelate. It may also be produced from sertraline hydrochloride solvate and hydrate forms, and crystallized from new solvent systems. Pharmaceutical compositions containing sertraline hydrochloride Form II and methods of treatment using such pharmaceutical compositions are also disclosed.

Abstract: This invention relates to crystalline polymorphs of sertraline hydrocloride, i.e. (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphtalenamine hydrochloride, denominated form I, II and V, and methods for their preparation.

Abstract: An acid salt of sertraline, wherein the acid is citric acid, fumaric acid, malic acid, maleic acid, malonic acid, phosphoric acid, succinic acid, sulfuric acid, L-tartaric acid, HBr, acetic acid, benzoic acid, benzenesulfonic acid, ethanesulfonic acid, lactic acid, methanesulfonic acid or toluenesulfonic acid. Similarly, a solvate of sertraline HCl, wherein the solvent is methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, t-butanol, acetic acid, ethyl acetate, or propylene glycol.

Abstract: This invention relates to a method for the preparation of sertraline hydrochloride, (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphtalenamine hydrochloride, in its crystalline form II.

Abstract: The novel metallocenes of the formula I in which, preferably, M1 is Zr or Hf, R1 and R2 are alkyl or halogen, R3 and R4 are hydrogen, R5 and R6 are alkyl or haloalkyl, —(CR8R9)m—R7—(CR8R9)n— is a single- or multi-membered chain in which R7 may also be a (substituted) hetero atom, m+n is zero or 1, and R10 is hydrogen, form, together with aluminoxanes as cocatalysts, a very effective catalyst system for the preparation of polyolefins of high stereospecificity and high melting point.